Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study

Luukkainen, Tapani; Allonen, H; Haukkamaa, Maija; Holma, Pentti; Pyörälä, Tapani; Terho, J; Toivonen, Juhani; Batar, I; Lampé, L; Andersson, Kerstin; Atterfeldt, Paula; Johansson, Elof D. B.; Nilsson, Staffan; Nygren, Karl-Gösta; Odlind, Viveca; Olsson, Sven-Eric; Rybo, Göran; Sikström, Bo; Nielsen, Niels Chr.; Buch, Annette; Osler, M; Steier, A; Ulstein, Magnar

doi:10.1016/0010-7824(87)90012-6

Cited by 122 publications

(55 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results are consistent with those reported earlier [8,9]. The irregular bleeding in the two groups was the major factor leading to discontinuation, which was more significant in Norplant-2 users than in LNG-IUD users.…”

Section: Discussionsupporting

confidence: 95%

Three years' experience with levonorgestrel-releasing intrauterine device and Norplant-2 implants: a randomized comparative study

Wang

Xin³

et al. 1992

Adv Contracept

View full text Add to dashboard Cite

A randomized comparative study of levonorgestrel-releasing intrauterine device (LNG-IUD) and Norplant-2 implants was carried out in 200 women for 36 months. Three thousand one hundred woman-months of use were observed with each device. Only one pregnancy occurred in users of LNG-IUD at the 12th month of use. The change in bleeding pattern was the most frequent reason for discontinuation. The discontinuation rate for irregular bleeding with Norplant-2 was 17.3 and 26.8 at 24 and 36 months, respectively, as compared to 3.3 with LNG-IUD at both 24 and 36 months. The differences were statistically significant. Removal for amenorrhea and pain only occurred in acceptors of LNG-IUD. About 20-40% of women using Norplant-2 had prolonged bleeding through 36 months. The percentage of amenorrhea in LNG-IUD was the highest (29.3%) at the end of two years of use. More than 97% of subjects reported satisfaction with the methods used by themselves.

show abstract

Section: Discussionsupporting

confidence: 95%

Three years' experience with levonorgestrel-releasing intrauterine device and Norplant-2 implants: a randomized comparative study

Wang

Xin³

et al. 1992

Adv Contracept

View full text Add to dashboard Cite

show abstract

“…A Finnish group* first conducted a small comparative study at two centers in Finland and one center in Brazil (the Fiuland/Brazil Study) [4,8,9]. This group subsequently coordinated a five-country study in Finland (four clinics), Sweden (four clinics), Denmark (two clinics), Hungary (one clinic), and Norway (one clinic) with a much larger study size (the European Study) [3,10,11]. Both studies used the Nova-T IUD as the comparative device, and reported five-year follow-up results.…”

Section: Methodsmentioning

confidence: 99%

The non-contraceptive effects of the levonorgestrel-releasing intrauterine device

Farr

1994

Adv Contracept

View full text Add to dashboard Cite

Clinical trials have consistently shown that the IUD that releases 20 micrograms levonorgestrel daily (LNG-IUD-20) has a contraceptive efficacy comparable to, if not surpassing, the Copper T380 and the Multiload Copper-375 IUDs. The focus of this review is the device's non-contraceptive effects--the beneficial ones, such as reduction of menorrhagia, a therapeutic effect on dysmenorrhea, and prevention of ectopic pregnancy, as well as the deleterious ones, such as amenorrhea, spotting and irregular bleeding, hormonal side-effects, and functional ovarian cysts. Also discussed are the possibility of a preventive effect on pelvic inflammatory disease, the effects of the IUD on postpartum/lactating women, fertility return after removal and other safety issues. In general, the LNG-IUD-20's non-contraceptive benefits are substantive, carry important medical and public health implications, and far outweigh the device's deleterious effects, which are either medically mild or transient in nature, and can usually be managed satisfactorily by counseling. A better understanding of these effects, both beneficial and deleterious, of this hormone-releasing IUD should lead to more effective patient counseling, which, in turn, should improve user quality of life, minimize unnecessary removals, and maximize continuation of use.

show abstract

“…Como o guideline não apresenta dados específicos para SIU-LNG, foi adotada a premissa de que mulheres em uso de SIU-LNG necessitam da mesma frequência de visitas médicas das mulheres em uso de DIU. (Luukkainen et al, 1987;Sivin c1990;Cox & Blacksell, 2000). d: O percentual de mulheres que engravidam enquanto usam DIU foi baseado no maior estudo que avaliou esse método (Sivin & Stern, 1979).…”

Section: Custo Com As Visitas Médicas De Acompanhamentounclassified

Custo-efetividade do uso do sistema intrauterino liberador de 52 mg de levonorgestrel (SIU-LNG) versus contraceptivos hormonais de curta duração na prevenção de gravidez não desejada em adolescentes entre 15 e 19 anos sob a perspectiva do Sistema Único de Saúde do Brasil (SUS)

Pepe¹,

Sakagute²,

Ramos³

et al. 2017

JBES

View full text Add to dashboard Cite

Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study

Cited by 122 publications

References 17 publications

Three years' experience with levonorgestrel-releasing intrauterine device and Norplant-2 implants: a randomized comparative study

Three years' experience with levonorgestrel-releasing intrauterine device and Norplant-2 implants: a randomized comparative study

The non-contraceptive effects of the levonorgestrel-releasing intrauterine device

Custo-efetividade do uso do sistema intrauterino liberador de 52 mg de levonorgestrel (SIU-LNG) versus contraceptivos hormonais de curta duração na prevenção de gravidez não desejada em adolescentes entre 15 e 19 anos sob a perspectiva do Sistema Único de Saúde do Brasil (SUS)

Contact Info

Product

Resources

About